Teplinsky Eleonora, Muggia Franco
New York University Cancer Institute, 160 East 34th Street, New York, NY 10016, USA.
Gynecol Oncol. 2014 Nov;135(2):364-70. doi: 10.1016/j.ygyno.2014.09.003. Epub 2014 Sep 16.
Targeting the human epidermal growth factor receptor 2 (HER2) has yielded major advances in breast cancer treatment. Accordingly, it has generated interest in targeting HER2 to treat gynecologic malignancies. Multiple studies have evaluated the rates of HER2 overexpression and/or amplification in ovarian and uterine cancers. HER2 has also been studied as a prognostic factor but resulting data has been contradictory. Moreover, clinical trials of HER2-directed therapies, including trastuzumab, pertuzumab, and lapatinib in ovarian and uterine cancers have been largely disappointing. Current research on HER2 in gynecologic malignancies has focused on identifying mechanisms of resistance and looking further into how HER2 signaling in gynecologic cancers differs from breast cancer. In this review, we highlight the existing data of targeting HER2 in ovarian and uterine carcinomas, many dating back more than a decade, and discuss future directions in pursuing HER2 as a potential target in these diseases.
靶向人类表皮生长因子受体2（HER2）在乳腺癌治疗方面取得了重大进展。因此，靶向HER2治疗妇科恶性肿瘤引起了人们的兴趣。多项研究评估了HER2在卵巢癌和子宫癌中的过表达率和/或扩增率。HER2也作为一种预后因素进行了研究，但结果数据相互矛盾。此外，HER2靶向治疗的临床试验，包括曲妥珠单抗、帕妥珠单抗和拉帕替尼在卵巢癌和子宫癌中的试验，大多令人失望。目前关于HER2在妇科恶性肿瘤中的研究主要集中在确定耐药机制，并进一步研究HER2信号在妇科癌症中与乳腺癌有何不同。在这篇综述中，我们重点介绍了靶向HER2治疗卵巢癌和子宫癌的现有数据，其中许多数据可追溯到十多年前，并讨论了将HER2作为这些疾病潜在靶点的未来研究方向。
